LY 900009

Drug Profile

LY 900009

Alternative Names: LY900009

Latest Information Update: 26 Oct 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Angiogenesis inhibitors; Apoptosis stimulants; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Oct 2012 Discontinued - Phase-I for Cancer in USA (PO)
  • 31 Aug 2012 Eli Lilly completes a phase I trial in Cancer in USA (NCT01158404)
  • 20 Jul 2010 Phase-I clinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top